grant

Functional Determinants of Metastatic Dormancy

Organization ALBERT EINSTEIN COLLEGE OF MEDICINELocation BRONX, UNITED STATESPosted 12 Jan 2022Deadline 30 Jun 2026
NIHUS FederalResearch GrantFY2025ATRAAdoptedAffectAfter CareAfter-TreatmentAftercareAgingAlveolar MacrophagesAutomobile DrivingAutoregulationBMP7BMP7 geneBSC-1 Cell Growth InhibitorBlood Precursor CellBody TissuesBone MarrowBone Marrow Reticuloendothelial SystemBone MetastasisBone cancer metastaticBony metastasisBreastBreast CancerCIF-BCSPG4CSPG4 geneCancer ModelCancer PatientCancer TreatmentCancerModelCancersCarcinomaCartilage-Inducing Factor-BCell Communication and SignalingCell SignalingCell SurvivalCell ViabilityClinical TrialsCuesDataEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelial cancerEvolutionG-TSFGSC-1GIGene TranscriptionGenesGenetic TranscriptionGlioblastoma-Derived T-Cell Suppressor FactorGoalsHematopoietic Progenitor CellsHematopoietic stem cellsHomeostasisHypoxiaHypoxicHypoxic tumorInflammatoryIntracellular Communication and SignalingLinkLungLung Respiratory SystemMCSPGMEL-CSPGMSK16MacrophageMalignant Breast NeoplasmMalignant CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMediatingMesenchymalMesenchymal Progenitor CellMesenchymal Stem CellsMesenchymal progenitorMesenchymal stromal/stem cellsMetastasisMetastasis to boneMetastasis to the LungMetastasizeMetastatic Cancer to the BoneMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the BoneMetastatic Neoplasm to the LungMetastatic TumorMetastatic Tumor to the BoneMetastatic Tumor to the LungMetastatic malignant neoplasm to boneMethodsMonitorNG2Neoplasm MetastasisOP1OrganOsseous metastasisOsteogenic Protein 1Oxygen DeficiencyPhysiological HomeostasisPolyerginPrimary LesionPrimary NeoplasmPrimary TumorProteinsPublishingPulmonary MacrophagesRNA ExpressionResidual CancersResting progenitorRetinoic AcidSecondary NeoplasmSecondary TumorSecondary cancer of boneSecondary malignancy of boneSecondary malignant neoplasm of boneSignal InductionSignal TransductionSignal Transduction SystemsSignalingSiteSkeletal metastasisSystemic diseaseTGF-Beta 2TGF-Beta2TGF-b2TGF-β2TGFB2TGFB2 geneTestingTherapeuticTissuesTrans Vitamin A AcidTranscriptionTransforming Growth Factor Beta 2TretinoinTretinoinumUpregulationVitamin A AcidWNT5AWNT5A geneWorkaberrant agingabnormal agingage associated effectsage effectage related effectsaged miceaged mouseaging effectall-trans-Retinoic Acidall-trans-Vitamin A acidanti-cancer therapybiological signal transductionblood cell progenitorblood progenitorblood stem cellblood-forming stem cellbone morphogenetic protein 7bone neoplasm secondarycancer cellcancer metastasiscancer therapycancer-directed therapydevelop therapydormant stem celldrivingdysfunctional age related changedysfunctional agingelderly miceepigeneticallyepithelial carcinomahematopoietic progenitorhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellimpact of ageimpaired agingimprintinactive stem cellinfluence of ageintervention developmentlatent progenitorlatent stem celllung metastasismaladaptive agingmalignancymalignant breast tumormesenchymal stromal cellmesenchymal stromal progenitor cellsmesenchymal-derived stem cellsmetastasize to the lungneoplasm/cancernestinnestin proteinneuron glial antigen 2novelold micepathological age related changespathological agingpluripotencypluripotent statepost treatmentprevent relapseprogenitor cell functionprogenitor cell nicheprogenitor functionprogenitor nicheprogramspulmonary metastasisquiescent progenitorquiescent stem cellsrational designrelapse preventionresponseresting stem cellstem and progenitor cell functionstem and progenitor cell nichestem and progenitor functionstem cell functionstem cell nichestem cell quiescencetherapy developmenttrans-Retinoic Acidtransforming growth factor beta2transforming growth factor β2treatment developmenttumor cell metastasistumor hypoxia
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

SUMMARY. The majority of cancer patients die of metastases originating from disseminated cancer cells
(DCCs), years and decades after treatment. This has been linked to the ability of DCCs to survive in a dormant

state and evade therapies. Our long-term goal is to understand dormancy of DCCs as a systemic disease

mechanism to target them and prevent relapse. Our overarching hypothesis is that complementary mechanism

between gene programs in primary lesions and target organs niche signals, converge to instruct DCCs in

target organs to enter dormancy via quiescence, pluripotency and survival programs. We further hypothesize

that such signals can be manipulated to suppress metastasis. Using epithelial cancer models we have

discovered that early dissemination spawns mesenchymal-like (M-Like) dormant breast cancer (BC) DCCs.

We also discovered that hypoxia in advanced primary tumors can prime DCC precursors to activate

quiescence programs and enter dormancy in target organs. Importantly, M-like early DCC precursors also

display a strong hypoxia response. Both early and late DCCs were found to respond to retinoic acid, WNT5A,

BMP7 and TGF2 signals derived from stromal target organ niches. These activate transcriptional programs

integrated by ZFP281 (a novel early DCC dormancy regulator) and NR2F1 to induce dormancy. Our new aims

build on these findings and explore three significant new discoveries: 1) Hypoxia signals in early and late

primary lesions turn on quiescence programs that epigenetically imprint DCC precursors to enter dormancy

when they arrive to target organs, 2) early or late DCCs that arrive to the bone marrow (BM) enter dormancy in

response to TGF2 and BMP7 produced by Nestin+/NG2+ mesenchymal stem cells (N+MSCs), which control

hematopoietic stem cells (HSCs) dormancy; loss of N+MSCs or TGF2 expression in these MSCs led to bone

metastasis and 3), in lungs, early and late DCCs reside in pro-dormancy niches orchestrated by alveolar

macrophages (AMs), which when depleted awaken dormant DCCs. We propose to study how signals from

primary lesion hypoxia along with BM and lung homeostatic niches are integrated to keep DCCs dormant. The

specific aims are: AIM 1. Determine how hypoxia primes DCCs for dormancy. AIM 2. Determine how

NG2+/Nestin+ MSCs orchestrate dormancy niches and how aging affects these mechanisms. AIM 3.

Determine how tissue resident lung alveolar macrophages (AMs) dictate DCC fate and how aging impacts the

function of these niches. Our proposal will integrate how primary lesions (early or late) may pre-program DCCs

for dormancy in defined target organ niches which further reinforce dormancy via specific cues, which may be

affected by aging. This approach will aid the design of rational methods to predict dormancy onset, monitor

residual cancer and develop therapies to induce and maintain dormancy or eradicate minimal residual cancer.

Grant Number: 5R01CA109182-23
NIH Institute/Center: NIH

Principal Investigator: Julio Aguirre-Ghiso

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →